LONDON (Alliance News) - Shares rose in Motif Bio PLC on Wednesday as it signed an agreement with Lamellar Biomedical to study the combination of Motif's iclaprim with Lamellar's Lamellasome product.
Shares in the antibiotics-focused biopharmaceutical company were 4.7% higher at 9.09 pence on Wednesday.
Under the agreement, Motif Bio will conduct an in vivo study evaluating its own antibiotic drug iclaprim with Lamellar's Lamellasome nucleic acid transfer program.
Iclaprim has been granted US orphan drug designation for Staphylococcus aureus pneumonia in patients with cystic fibrosis.
Lamellasome candidate LMS-611 which has mucus clearing properties, has so far demonstrated the ability to enhance certain properties of antibiotics and currently has a European orphan drug designation for cystic fibrosis.
"We have been looking for a way to optimise the development of iclaprim in patients with CF. We are excited about the preliminary data we have seen with Lamellar's technology and look forward to evaluating it in combination with iclaprim," said Chief Executive Officer Graham Lumsden.
